Evidence map›Paper›PMID 42281682›Full record

ArticleCureus2026

The First Moroccan Experience of Personalized Template‑Guided High-Dose-Rate Brachytherapy for Organ Preservation in Glans Squamous Cell Carcinoma: Game Changer or Challenge?

Hamza Samlali, Najlaa Assaid, Youness Khobbaizi, Redouane Samlali, Hassan Jouhadi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hamza SamlaliRadiation Oncology Department, Littoral Clinic - Oncorad Group, Casablanca, MAR.
Najlaa AssaidResearch Department, Littoral Clinic - Oncorad Group, Casablanca, MAR.
Youness KhobbaiziMedical Physics Department, Littoral Clinic - Oncorad Group, Casablanca, MAR.
Redouane SamlaliRadiation Oncology Department, Littoral Clinic - Oncorad Group, Casablanca, MAR.
Hassan JouhadiRadiation Oncology, University Hospital Center Ibn Rochd, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous cell carcinoma of the glans is a rare malignancy, often diagnosed at an advanced stage, and its management remains challenging. Therapeutic approaches are multimodal and depend on tumor stage, risk of recurrence, nodal involvement, and disease extent. Organ-preserving strategies are increasingly advocated, particularly in patients who refuse mutilating surgery. We report the first Moroccan case of a 50-year-old man diagnosed with a T2N0M0 glans carcinoma, treated with high-dose-rate (HDR) brachytherapy using a customized template following refusal of partial penectomy. Initial treatment achieved adequate tumor coverage without acute toxicity, with no evidence of necrosis or skin ulceration. A superficial recurrence in the previously irradiated area was detected four months later and was successfully treated with salvage HDR brachytherapy. At 18 months of follow-up, urinary function was preserved and partial sexual function maintained, with no severe complications. This case illustrates that personalized HDR brachytherapy may represent a feasible, safe, and organ-preserving alternative in patients refusing mutilating surgery, supporting its applicability even in resource-limited settings.

Indexed as

glans squamous cell carcinomahigh-dose-rate brachytherapyorgan preservationpenile cancerpersonalized template

Identifiers

PMID42281682
PMCPMC13252689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.